United Therapeutics develops and commercializes therapies for rare and serious diseases, with a long-standing focus on pulmonary arterial hypertension (PAH) and related cardiopulmonary conditions. Its marketed portfolio has included prostacyclin-pathway and other specialty medicines delivered by infusion, inhalation, and oral routes. The company also invests in regenerative medicine and organ-manufacturing research aimed at transplant shortages. Customers are mainly specialty physicians and patients in niche cardiopulmonary markets.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q1 2025 | 794.4 | — | 322.2 | 11% |
| Q2 2025 | 798.6 | — | 309.5 | 18.5% |
| Q3 2025 | 799.5 | — | 338.7 | 7.6% |
| Q4 2025 | 790.2 | — | 364.3 | 31.8% |
| Q1 2026 | 781.5 | -1.6% | 274.9 | -14.7% |
| Q2 2026 | 783.3 | -1.9% | 333 | 7.6% |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: First Solar, Inc. (FSLR), Guardant Health, Inc. (GH), TPG Inc. (TPG), Entegris, Inc. (ENTG), Charter Communications, Inc. (CHTR), Genmab A/S (GMAB)